Domiren

Take Domiren-10 mg tablet orally, 15-30 minutes before meals. Do not chew or crush the tablet; swallow it whole with water.

Domperidone acts as a peripheral dopamine D2 receptor antagonist, primarily in the chemoreceptor trigger zone (CTZ) and in the gut. By blocking dopamine receptors, it increases lower esophageal sphincter tone, improves gastric motility and emptying, and reduces emesis without significantly crossing the blood-brain barrier.

• Known hypersensitivity to Domperidone or any excipients
• Prolactinoma (a pituitary tumour)
• Moderate to severe hepatic impairment
• Conditions where gastrointestinal motility stimulation is dangerous (e.g., gastrointestinal haemorrhage, mechanical obstruction, perforation)
• Patients with known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant uncorrected electrolyte disturbances or underlying cardiac diseases (e.g., congestive heart failure)
• Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin, verapamil, diltiazem)
• Concomitant use with QTc-prolonging drugs

Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.

Symptoms of overdose include somnolence, disorientation, extrapyramidal reactions, and QT prolongation. Treatment should be symptomatic and supportive. Gastric lavage and activated charcoal may be considered if appropriate. ECG monitoring is recommended due to the risk of QT prolongation and cardiac arrhythmias.

Pregnancy: Use should be avoided unless the potential benefits outweigh the potential risks. Animal studies do not indicate direct or indirect harmful effects on reproductive toxicity. Lactation: Domperidone is excreted in breast milk in small amounts. A risk to the breast-fed infant cannot be excluded, especially with doses over 30mg daily. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Domperidone therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

• Known hypersensitivity to Domperidone or any excipients
• Prolactinoma (a pituitary tumour)
• Moderate to severe hepatic impairment
• Conditions where gastrointestinal motility stimulation is dangerous (e.g., gastrointestinal haemorrhage, mechanical obstruction, perforation)
• Patients with known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant uncorrected electrolyte disturbances or underlying cardiac diseases (e.g., congestive heart failure)
• Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin, verapamil, diltiazem)
• Concomitant use with QTc-prolonging drugs

Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.

Symptoms of overdose include somnolence, disorientation, extrapyramidal reactions, and QT prolongation. Treatment should be symptomatic and supportive. Gastric lavage and activated charcoal may be considered if appropriate. ECG monitoring is recommended due to the risk of QT prolongation and cardiac arrhythmias.

Pregnancy: Use should be avoided unless the potential benefits outweigh the potential risks. Animal studies do not indicate direct or indirect harmful effects on reproductive toxicity. Lactation: Domperidone is excreted in breast milk in small amounts. A risk to the breast-fed infant cannot be excluded, especially with doses over 30mg daily. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Domperidone therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.